Year |
Citation |
Score |
2023 |
Fernandez HH, Macklin EA, Hauser RA, Chou KL, Cakmak YO, Ozsoy B, Fahn S. Intrinsic auricular muscle zone stimulation for Parkinson disease: The EARSTIM-PD Phase II multi-center pilot study results. Parkinsonism & Related Disorders. 105959. PMID 38246833 DOI: 10.1016/j.parkreldis.2023.105959 |
0.317 |
|
2023 |
Vijayakumari AA, Fernandez HH, Walter BL. MRI-based multivariate gray matter volumetric distance for predicting motor symptom progression in Parkinson's disease. Scientific Reports. 13: 17704. PMID 37848592 DOI: 10.1038/s41598-023-44322-0 |
0.319 |
|
2023 |
Vijayakumari AA, Mandava N, Hogue O, Fernandez HH, Walter BL. A novel MRI-based volumetric index for monitoring the motor symptoms in Parkinson's disease. Journal of the Neurological Sciences. 453: 120813. PMID 37742348 DOI: 10.1016/j.jns.2023.120813 |
0.345 |
|
2023 |
Alberts JL, Shuaib U, Fernandez H, Walter BL, Schindler D, Miller Koop M, Rosenfeldt AB. The Parkinson's disease waiting room of the future: measurements, not magazines. Frontiers in Neurology. 14: 1212113. PMID 37670776 DOI: 10.3389/fneur.2023.1212113 |
0.331 |
|
2023 |
Fernandez HH, Odin P, Standaert DG, Henriksen T, Jimenez-Shahed J, Metz S, Alobaidi A, Yan CH, Kukreja P, Parra JC, Zamudio J, Onuk K, Wright J, Antonini A. Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson's disease continuum: Revelations from the MANAGE-PD validation cohort. Parkinsonism & Related Disorders. 105514. PMID 37563079 DOI: 10.1016/j.parkreldis.2023.105514 |
0.348 |
|
2023 |
Kundrick A, Hogue O, Namrow S, Samala R, Walter E, Walter B, Fernandez H, Margolius A. Adopting a palliative care mindset is an unmet need in Parkinson's disease. Clinical Parkinsonism & Related Disorders. 9: 100206. PMID 37448833 DOI: 10.1016/j.prdoa.2023.100206 |
0.322 |
|
2021 |
Antonini A, Odin P, Schmidt P, Cubillos F, Standaert DG, Henriksen T, Jimenez-Shahed J, Alobaidi A, Jalundhwala YJ, Bao Y, Zamudio J, Parra JC, Kukreja P, Onuk K, Skalicky AM, ... ... Fernandez HH, et al. Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications. Parkinsonism & Related Disorders. 92: 59-66. PMID 34695657 DOI: 10.1016/j.parkreldis.2021.10.009 |
0.341 |
|
2021 |
Hauser RA, Hattori N, Fernandez H, Isaacson SH, Mochizuki H, Rascol O, Stocchi F, Li J, Mori A, Nakajima Y, Ristuccia R, LeWitt P. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. Journal of Parkinson's Disease. PMID 34486986 DOI: 10.3233/JPD-212672 |
0.319 |
|
2021 |
Salles PA, Mata IF, Fernandez HH. Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view. Parkinsonism & Related Disorders. 88: 51-57. PMID 34119931 DOI: 10.1016/j.parkreldis.2021.05.013 |
0.31 |
|
2021 |
Isaacson SH, Ballard CG, Kreitzman DL, Coate B, Norton JC, Fernandez HH, Ilic TV, Azulay JP, Ferreira JJ, Abler V, Stankovic S. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients. Parkinsonism & Related Disorders. 87: 25-31. PMID 33933853 DOI: 10.1016/j.parkreldis.2021.04.012 |
0.312 |
|
2021 |
Alberts JL, Koop MM, McGinley MP, Penko AL, Fernandez HH, Shook S, Bermel RA, Machado A, Rosenfeldt AB. Use of a Smartphone to Gather Parkinson's Disease Neurological Vital Signs during the COVID-19 Pandemic. Parkinson's Disease. 2021: 5534282. PMID 33868630 DOI: 10.1155/2021/5534282 |
0.342 |
|
2021 |
Kleiner G, Fernandez HH, Chou KL, Fasano A, Duque KR, Hengartner D, Law A, Margolius A, Poon YY, Sáenz Farret M, Saleh P, Vizcarra JA, Stebbins GT, Espay AJ. Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33590555 DOI: 10.1002/mds.28507 |
0.302 |
|
2020 |
Sy MAC, Fernandez HH. Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD). Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 32935299 DOI: 10.1007/S13311-020-00924-4 |
0.475 |
|
2020 |
Uchida A, Pillai JA, Bermel R, Jones SE, Fernandez H, Leverenz JB, Srivastava SK, Ehlers JP. Correlation between brain volume and retinal photoreceptor outer segment volume in normal aging and neurodegenerative diseases. Plos One. 15: e0237078. PMID 32881874 DOI: 10.1371/Journal.Pone.0237078 |
0.307 |
|
2020 |
Hauser RA, Barkay H, Fernandez HH, Factor SA, Jimenez-Shahed J, Gross N, Marinelli L, Forrest Gordon M, Savola JM, Anderson KE. 134 Long-Term Deutetrabenazine Treatment Is Associated with Sustained Treatment Response in Tardive Dyskinesia: Results from an Open-Label Extension Study. Cns Spectrums. 25: 284-285. PMID 32331048 DOI: 10.1017/S1092852920000504 |
0.3 |
|
2020 |
Fernandez HH, Barkay H, Hauser RA, Factor SA, Jimenez-Shahed J, Gross N, Marinelli L, Gordon MF, Savola JM, Anderson KE. 151 Confirmed Safety of Deutet.rabenazine for Tardive Dyskinesia in a 3-Year Open-Label Extension Study. Cns Spectrums. 25: 296-297. PMID 32331030 DOI: 10.1017/S109285292000067X |
0.316 |
|
2020 |
Bhidayasiri R, Panyakaew P, Trenkwalder C, Jeon B, Hattori N, Jagota P, Wu YR, Moro E, Lim SY, Shang H, Rosales R, Lee JY, Thit WM, Tan EK, Lim TT, ... ... Fernandez HH, et al. Delivering patient-centered care in Parkinson's disease: Challenges and consensus from an international panel. Parkinsonism & Related Disorders. 72: 82-87. PMID 32146380 DOI: 10.1016/J.Parkreldis.2020.02.013 |
0.477 |
|
2019 |
Mishra VR, Sreenivasan KR, Yang Z, Zhuang X, Cordes D, Mari Z, Litvan I, Fernandez HH, Eidelberg D, Ritter A, Cummings JL, Walsh RR. Unique white matter structural connectivity in early-stage, drug-naive Parkinson disease. Neurology. PMID 31882528 DOI: 10.1212/Wnl.0000000000008867 |
0.392 |
|
2019 |
Abboud H, Genc G, Saad S, Thompson N, Oravivattanakul S, Alsallom F, Yu XX, Floden D, Gostkowski M, Ahmed A, Ezzeldin A, Marouf HM, Mansour OY, Fernandez HH. Factors Associated With Postoperative Confusion and Prolonged Hospital Stay Following Deep Brain Stimulation Surgery for Parkinson Disease. Neurosurgery. PMID 31432068 DOI: 10.1093/Neuros/Nyz316 |
0.354 |
|
2019 |
Abboud H, Reyes D, Genc G, Ahmed A, Gostkowski M, Fernandez HH. Height and weight changes after deep brain stimulation in patients with Parkinson disease: role of clinical subtypes. Heliyon. 5: e01862. PMID 31304406 DOI: 10.1016/J.Heliyon.2019.E01862 |
0.423 |
|
2019 |
Abboud H, Macaron G, Yu XX, Knusel K, Fernandez HH, Bethoux F. Defining the spectrum of spasticity-associated involuntary movements. Parkinsonism & Related Disorders. PMID 31109729 DOI: 10.1016/J.Parkreldis.2019.05.007 |
0.327 |
|
2019 |
Moro E, Fernandez HH. Highlights of the XXIII World Congress on Parkinson's Disease and Related Disorders. Parkinsonism & Related Disorders. 59: 1. PMID 31029231 DOI: 10.1016/J.Parkreldis.2019.03.011 |
0.392 |
|
2019 |
Hauser RA, Fernandez HH, Stamler D, Davis MD, Factor SA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, LeDoux MS, Shprecher DR, Anderson KE. 45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study. Cns Spectrums. 24: 200-201. PMID 30859973 DOI: 10.1017/S1092852919000385 |
0.312 |
|
2019 |
Anderson KE, Stamler D, Davis MD, Gross N, Hauser RA, Jarskog LF, Jimenez-Shahed J, Kumar R, Ochudlo S, McEvoy J, Fernandez HH. 35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia. Cns Spectrums. 24: 193-194. PMID 30859964 DOI: 10.1017/S1092852919000294 |
0.338 |
|
2019 |
Anderson KE, Stamler D, Davis MD, Hauser RA, Jarskog LF, Jimenez-Shahed J, Kumar R, Ochudlo S, McEvoy J, Fernandez HH. 34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities. Cns Spectrums. 24: 193. PMID 30859963 DOI: 10.1017/S1092852919000282 |
0.353 |
|
2019 |
Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, ... ... Fernandez HH, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 92: 329-337. PMID 30745444 DOI: 10.1212/Wnl.0000000000006926 |
0.355 |
|
2019 |
LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Neurology. 18: 145-154. PMID 30663606 DOI: 10.1016/S1474-4422(18)30405-8 |
0.436 |
|
2019 |
Hengartner D, Fernandez HH. The next chapter in symptomatic Parkinson disease treatments. Parkinsonism & Related Disorders. PMID 30661840 DOI: 10.1016/J.Parkreldis.2019.01.002 |
0.455 |
|
2018 |
Margolius A, Fernandez HH. Current treatment of tardive dyskinesia. Parkinsonism & Related Disorders. PMID 30591350 DOI: 10.1016/J.Parkreldis.2018.12.022 |
0.334 |
|
2018 |
Bhidayasiri R, Rattanachaisit W, Phokaewvarangkul O, Lim TT, Fernandez HH. Exploring bedside clinical features of parkinsonism: A focus on differential diagnosis. Parkinsonism & Related Disorders. PMID 30502095 DOI: 10.1016/J.Parkreldis.2018.11.005 |
0.327 |
|
2018 |
Burack M, Aldred J, Zadikoff C, Vanagunas A, Klos K, Bilir B, Fernandez HH, Standaert DG. Implementing Levodopa-Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners. Movement Disorders Clinical Practice. 5: 383-393. PMID 30363427 DOI: 10.1002/Mdc3.12630 |
0.395 |
|
2018 |
Pillai JA, Bonner-Jackson A, Floden D, Fernandez H, Leverenz JB. Lack of Accurate Self-appraisal is Equally Likely in MCI from Parkinson's Disease and Alzheimer's Disease. Movement Disorders Clinical Practice. 5: 283-289. PMID 30363404 DOI: 10.1002/Mdc3.12606 |
0.411 |
|
2018 |
Siddiqui JH, Aldaajani Z, Mehanna R, Changizi BK, Bhatti D, Al-Johani ZG, Shukla AW, Fernandez HH, Bajwa JA. Rationale and patient selection for interventional therapies in Parkinson's disease. Expert Review of Neurotherapeutics. PMID 30328737 DOI: 10.1080/14737175.2018.1535902 |
0.443 |
|
2018 |
Hogue O, Fernandez HH, Floden DP. Predicting early cognitive decline in newly-diagnosed Parkinson's patients: A practical model. Parkinsonism & Related Disorders. PMID 29936131 DOI: 10.1016/J.Parkreldis.2018.06.031 |
0.357 |
|
2018 |
Frizon LA, Nagel SJ, May FJ, Shao J, Maldonado-Naranjo AL, Fernandez HH, Machado AG. Outcomes following deep brain stimulation lead revision or reimplantation for Parkinson's disease. Journal of Neurosurgery. 1-6. PMID 29932378 DOI: 10.3171/2018.1.Jns171660 |
0.408 |
|
2018 |
Uchida A, Pillai JA, Bermel R, Bonner-Jackson A, Rae-Grant A, Fernandez H, Bena J, Jones SE, Leverenz JB, Srivastava SK, Ehlers JP. Outer Retinal Assessment Using Spectral-Domain Optical Coherence Tomography in Patients With Alzheimer's and Parkinson's Disease. Investigative Ophthalmology & Visual Science. 59: 2768-2777. PMID 29860463 DOI: 10.1167/Iovs.17-23240 |
0.306 |
|
2018 |
Mehanna R, Fernandez HH, Wagle Shukla A, Bajwa JA. Deep Brain Stimulation in Parkinson's Disease. Parkinson's Disease. 2018: 9625291. PMID 29755729 DOI: 10.1155/2018/9625291 |
0.41 |
|
2018 |
Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, et al. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29570853 DOI: 10.1002/Mds.27338 |
0.387 |
|
2018 |
Chou KL, Stacy M, Simuni T, Miyasaki J, Oertel WH, Sethi K, Fernandez HH, Stocchi F. The spectrum of "off" in Parkinson's disease: What have we learned over 40 years? Parkinsonism & Related Disorders. PMID 29456046 DOI: 10.1016/J.Parkreldis.2018.02.001 |
0.392 |
|
2018 |
Bonifati V, Fernandez HH. The beginning of our new journey. Parkinsonism & Related Disorders. 46: 2. PMID 29295734 DOI: 10.1016/J.Parkreldis.2017.12.028 |
0.326 |
|
2018 |
Rasameesoraj T, Yu XX, Patel S, Fernandez HH. Is levodopa-carbidopa intestinal gel over- or under-utilized? A review of current evidence. Medical Research Archives. 6. DOI: 10.18103/Mra.V6I2.1595 |
0.406 |
|
2018 |
Anderson KE, Davis MD, Factor SA, Hauser RA, Jarskog LF, Jimenez-Shahed J, Kumar R, Ochudlo S, Ondo WG, Fernandez HH. 158 Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study Cns Spectrums. 23: 97-97. DOI: 10.1017/S1092852918000500 |
0.32 |
|
2018 |
Fernandez HH, Davis MD, Factor SA, Hauser RA, Jarskog LF, Jimenez-Shahed J, Kumar R, Ochudlo S, Ondo WG, Anderson KE. 134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies Cns Spectrums. 23: 84-84. DOI: 10.1017/S1092852918000305 |
0.364 |
|
2017 |
Mehanna R, Bajwa JA, Fernandez H, Shukla AAW. Cognitive Impact of Deep Brain Stimulation on Parkinson's Disease Patients. Parkinson's Disease. 2017: 3085140. PMID 29359065 DOI: 10.1155/2017/3085140 |
0.421 |
|
2017 |
Wagle Shukla A, Zeilman P, Fernandez H, Bajwa JA, Mehanna R. DBS Programming: An Evolving Approach for Patients with Parkinson's Disease. Parkinson's Disease. 2017: 8492619. PMID 29147598 DOI: 10.1155/2017/8492619 |
0.317 |
|
2017 |
Heldman DA, Urrea-Mendoza E, Lovera LC, Schmerler DA, Garcia X, Mohammad ME, McFarlane MCU, Giuffrida JP, Espay AJ, Fernandez HH. App-Based Bradykinesia Tasks for Clinic and Home Assessment in Parkinson's Disease: Reliability and Responsiveness. Journal of Parkinson's Disease. PMID 28922169 DOI: 10.3233/Jpd-171159 |
0.42 |
|
2017 |
Abboud H, Genc G, Thompson NR, Oravivattanakul S, Alsallom F, Reyes D, Wilson K, Cerejo R, Yu XX, Floden D, Ahmed A, Gostkowski M, Ezzeldin A, Marouf H, Mansour OY, ... ... Fernandez HH, et al. Predictors of Functional and Quality of Life Outcomes following Deep Brain Stimulation Surgery in Parkinson's Disease Patients: Disease, Patient, and Surgical Factors. Parkinson's Disease. 2017: 5609163. PMID 28852579 DOI: 10.1155/2017/5609163 |
0.421 |
|
2017 |
Patel S, Ojo O, Genc G, Oravivattanakul S, Huo Y, Rasameesoraj T, Wang L, Bena J, Drerup M, Foldvary-Schaefer N, Ahmed A, Fernandez HH. A Computerized Cognitive behavioral therapy Randomized, Controlled, pilot trial for insomnia in Parkinson Disease (ACCORD-PD). Journal of Clinical Movement Disorders. 4: 16. PMID 28852567 DOI: 10.1186/s40734-017-0062-2 |
0.347 |
|
2017 |
Pasco PMD, Jamora RDG, Rosales RL, Diesta CCE, Ng AR, Teleg RA, Go CL, Lee L, Fernandez HH. Validation of the XDP-MDSP rating scale for the evaluation of patients with X-linked dystonia-parkinsonism. Npj Parkinson's Disease. 3: 24. PMID 28761929 DOI: 10.1038/S41531-017-0026-0 |
0.322 |
|
2017 |
Patel S, Garcia X, Mohammad ME, Yu XX, Vlastaris K, O'Donnell K, Sutton K, Fernandez HH. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center. Journal of the Neurological Sciences. 379: 308-311. PMID 28716269 DOI: 10.1016/J.Jns.2017.06.022 |
0.419 |
|
2017 |
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Psychiatry. PMID 28668671 DOI: 10.1016/S2215-0366(17)30236-5 |
0.344 |
|
2017 |
Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, et al. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28233927 DOI: 10.1002/Mds.26913 |
0.46 |
|
2017 |
Yu XX, Fernandez HH. Dopamine agonist withdrawal syndrome: A comprehensive review. Journal of the Neurological Sciences. PMID 28104232 DOI: 10.1016/J.Jns.2016.12.070 |
0.37 |
|
2016 |
Oravivattanakul S, Benchaya L, Wu G, Ahmed A, Itin I, Cooper S, Gostkowski M, Rudolph J, Appleby K, Sweeney P, Fernandez HH. Dopamine Transporter (DaT) Scan Utilization in a Movement Disorder Center. Movement Disorders Clinical Practice. 3: 31-35. PMID 30363515 DOI: 10.1002/Mdc3.12261 |
0.317 |
|
2016 |
Fernandez HH, Robieson WZ, Chatamra K, Dubow J, Eaton S, Benesh JA, Odin P. Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson's disease. Npj Parkinson's Disease. 2: 16015. PMID 28725698 DOI: 10.1038/Npjparkd.2016.15 |
0.508 |
|
2016 |
Brys M, Fox MD, Agarwal S, Biagioni M, Dacpano G, Kumar P, Pirraglia E, Chen R, Wu A, Fernandez H, Shukla AW, Lou JS, Gray Z, Simon DK, Di Rocco A, et al. Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial. Neurology. PMID 27708129 DOI: 10.1212/Wnl.0000000000003279 |
0.416 |
|
2016 |
Ojo OO, Fernandez HH. Current Understanding of Psychosis in Parkinson's Disease. Current Psychiatry Reports. 18: 97. PMID 27629356 DOI: 10.1007/S11920-016-0730-1 |
0.461 |
|
2016 |
Pillai JA, Bermel R, Bonner-Jackson A, Rae-Grant A, Fernandez H, Bena J, Jones SE, Ehlers JP, Leverenz JB. Retinal Nerve Fiber Layer Thinning in Alzheimer's Disease: A Case-Control Study in Comparison to Normal Aging, Parkinson's Disease, and Non-Alzheimer's Dementia. American Journal of Alzheimer's Disease and Other Dementias. PMID 26888864 DOI: 10.1177/1533317515628053 |
0.342 |
|
2015 |
Bega D, Luo S, Fernandez H, Chou K, Aminoff M, Parashos S, Walker H, Russell DS, Christine CW, Dhall R, Singer C, Bodis-Wollner I, Hamill R, Truong D, Mari Z, et al. Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease. Movement Disorders Clinical Practice. 2: 371-378. PMID 28393083 DOI: 10.1002/Mdc3.12205 |
0.398 |
|
2015 |
Lim TT, Kluger BM, Rodriguez RL, Malaty IA, Palacio R, Ojo OO, Patel S, Gujrati Y, Nutter B, Swartz C, Hennessy C, Fernandez HH. Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1825-30. PMID 26769459 DOI: 10.1002/Mds.26429 |
0.462 |
|
2015 |
Lang AE, Rodriguez RL, Boyd JT, Chouinard S, Zadikoff C, Espay AJ, Slevin JT, Fernandez HH, Lew MF, Stein DA, Odin P, Fung VS, Klostermann F, Fasano A, Draganov PV, et al. Integrated Safety of Levodopa-Carbidopa Intestinal Gel From Prospective Clinical Trials. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26695437 DOI: 10.1002/Mds.26485 |
0.411 |
|
2015 |
Fernandez HH. 2015 Update on Parkinson disease. Cleveland Clinic Journal of Medicine. 82: 563-8. PMID 26366951 DOI: 10.3949/Ccjm.82Gr.15004 |
0.406 |
|
2015 |
Trenkwalder C, Chaudhuri KR, García Ruiz PJ, LeWitt P, Katzenschlager R, Sixel-Döring F, Henriksen T, Sesar Á, Poewe W, Baker M, Ceballos-Baumann A, Deuschl G, Drapier S, Ebersbach G, ... ... Fernandez H, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations. Parkinsonism & Related Disorders. 21: 1023-30. PMID 26189414 DOI: 10.1016/J.Parkreldis.2015.06.012 |
0.484 |
|
2015 |
Fernandez HH, Standaert DG, Chatamra K, Benesh JA. Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1435-6. PMID 26179940 DOI: 10.1002/Mds.26316 |
0.412 |
|
2015 |
Genc G, Abboud H, Oravivattanakul S, Alsallom F, Thompson NR, Cooper S, Gostkowski M, Machado A, Fernandez HH. Socioeconomic Status May Impact Functional Outcome of Deep Brain Stimulation Surgery in Parkinson's Disease. Neuromodulation : Journal of the International Neuromodulation Society. PMID 26076401 DOI: 10.1111/Ner.12324 |
0.422 |
|
2015 |
Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, Chatamra K, Benesh J. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients. Journal of Parkinson's Disease. 5: 165-74. PMID 25588353 DOI: 10.3233/Jpd-140456 |
0.36 |
|
2015 |
Abboud H, Floden D, Thompson NR, Genc G, Oravivattanakul S, Alsallom F, Swa B, Kubu C, Pandya M, Gostkowski M, Cooper S, Machado AG, Fernandez HH. Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson's disease. Parkinsonism & Related Disorders. 21: 249-53. PMID 25578289 DOI: 10.1016/J.Parkreldis.2014.12.018 |
0.398 |
|
2015 |
Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 500-9. PMID 25545465 DOI: 10.1002/Mds.26123 |
0.453 |
|
2015 |
Ojo OO, Fernandez HH. Levodopa/carbidopa intestinal gel: An effective formulation for the management of advanced Parkinson's disease Future Neurology. 10: 191-201. DOI: 10.2217/Fnl.15.5 |
0.49 |
|
2014 |
Abboud H, Mehanna R, Machado A, Ahmed A, Gostkowski M, Cooper S, Itin I, Sweeney P, Pandya M, Kubu C, Floden D, Ford PJ, Fernandez HH. Comprehensive, Multidisciplinary Deep Brain Stimulation Screening for Parkinson Patients: No Room for "Short Cuts". Movement Disorders Clinical Practice. 1: 336-341. PMID 30363983 DOI: 10.1002/Mdc3.12090 |
0.467 |
|
2014 |
Okun MS, Wu SS, Jennings D, Marek K, Rodriguez RL, Fernandez HH. Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort. Journal of Clinical Movement Disorders. 1: 8. PMID 26788334 DOI: 10.1186/2054-7072-1-8 |
0.365 |
|
2014 |
Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, ... ... Fernandez HH, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. Jama Neurology. 71: 543-52. PMID 24664227 DOI: 10.1001/Jamaneurol.2014.131 |
0.398 |
|
2014 |
Oravivattanakul S, Abboud H, Fernandez H, Itin I. Unusual case of levodopa-responsive camptocormia in a patient with negative dopamine transporter scan and normal DYT 5 gene. Clinical Neuropharmacology. 37: 63-64. PMID 24614670 DOI: 10.1097/Wnf.0000000000000024 |
0.328 |
|
2014 |
Hassan A, Vallabhajosula S, Zahodne LB, Bowers D, Okun MS, Fernandez HH, Hass CJ. Correlations of apathy and depression with postural instability in Parkinson disease. Journal of the Neurological Sciences. 338: 162-5. PMID 24461565 DOI: 10.1016/J.Jns.2013.12.040 |
0.356 |
|
2014 |
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. The Lancet. Neurology. 13: 141-9. PMID 24361112 DOI: 10.1016/S1474-4422(13)70293-X |
0.389 |
|
2014 |
Mehanna R, Fernandez HH. Treatment of parkinsonism in patients with non-Parkinson dementia Movement Disorders in Dementias. 61-71. DOI: 10.1007/978-1-4471-6365-7_4 |
0.31 |
|
2014 |
Alsallom F, Fernandez HH. Treatment of the elderly with Parkinson's disease: Rationale for using levodopa and practical advice for best management Focus On Parkinson's Disease. 24: 6-15. |
0.333 |
|
2013 |
Simuni T, Luo ST, Chou KL, Fernandez H, He B, Parashos S. Rankin scale as a potential measure of global disability in early Parkinson's disease. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 20: 1200-3. PMID 23810387 DOI: 10.1016/J.Jocn.2012.10.030 |
0.438 |
|
2013 |
Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, Chatamra K, Benesh J, Pritchett Y, Hass SL, Lenz RA. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism & Related Disorders. 19: 339-45. PMID 23287001 DOI: 10.1016/J.Parkreldis.2012.11.020 |
0.483 |
|
2013 |
Lim TT, Ahmed A, Itin I, Gostkowski M, Rudolph J, Cooper S, Fernandez HH. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease? The International Journal of Neuroscience. 123: 170-4. PMID 23078283 DOI: 10.3109/00207454.2012.732976 |
0.468 |
|
2013 |
Cooper SE, McIntyre CC, Fernandez HH, Vitek JL. Association of deep brain stimulation washout effects with Parkinson disease duration. Jama Neurology. 70: 95-9. PMID 23070397 DOI: 10.1001/Jamaneurol.2013.581 |
0.47 |
|
2013 |
Espay A, Odin P, Fernandez H, Hauser R, Standaert D, Lang A, Fung V, Klostermann F, Robieson W, Chatamra K, Benesh J. A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: safety and motor-symptom endpoints Journal of the Neurological Sciences. 333: e127. DOI: 10.1016/J.Jns.2013.07.426 |
0.4 |
|
2013 |
Standaert D, Fernandez H, Odin P, Hauser R, Espay A, Steiger M, Chouinard S, Suchowersky O, Yakupov E, Merikle E, Robieson W, Chatamra K, Benesh J. A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: Functional and health-related quality-of-life endpoints Journal of the Neurological Sciences. 333: e123-e124. DOI: 10.1016/J.Jns.2013.07.413 |
0.345 |
|
2012 |
Fernandez HH. Nonmotor complications of Parkinson disease. Cleveland Clinic Journal of Medicine. 79: S14-8. PMID 22761264 DOI: 10.3949/Ccjm.79.S2A.03 |
0.459 |
|
2012 |
Kluger BM, Parra V, Jacobson C, Garvan CW, Rodriguez RL, Fernandez HH, Fogel A, Skoblar BM, Bowers D, Okun MS. The prevalence of fatigue following deep brain stimulation surgery in Parkinson's disease and association with quality of life. Parkinson's Disease. 2012: 769506. PMID 22666631 DOI: 10.1155/2012/769506 |
0.403 |
|
2012 |
Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 78: 1229-36. PMID 22496199 DOI: 10.1212/Wnl.0B013E3182516244 |
0.398 |
|
2012 |
Oyama G, Rodriguez RL, Jones JD, Swartz C, Merritt S, Unger R, Hubmann M, Delgado A, Simon E, Doniger GM, Bowers D, Foote KD, Fernandez HH, Okun MS. Selection of deep brain stimulation candidates in private neurology practices: referral may be simpler than a computerized triage system. Neuromodulation : Journal of the International Neuromodulation Society. 15: 246-50; discussion 2. PMID 22376158 DOI: 10.1111/J.1525-1403.2012.00437.X |
0.421 |
|
2012 |
Machado A, Fernandez HH, Deogaonkar M. Deep brain stimulation: what can patients expect from it? Cleveland Clinic Journal of Medicine. 79: 113-20. PMID 22301561 DOI: 10.3949/Ccjm.78Gr.11006 |
0.377 |
|
2012 |
Fernandez HH. Updates in the medical management of Parkinson disease. Cleveland Clinic Journal of Medicine. 79: 28-35. PMID 22219231 DOI: 10.3949/Ccjm.78Gr.11005 |
0.41 |
|
2012 |
Bernal-Pacheco O, Limotai N, Go CL, Fernandez HH. Nonmotor manifestations in Parkinson disease. The Neurologist. 18: 1-16. PMID 22217609 DOI: 10.1097/Nrl.0B013E31823D7Abb |
0.469 |
|
2012 |
Goldman SM, Quinlan PJ, Ross GW, Marras C, Meng C, Bhudhikanok GS, Comyns K, Korell M, Chade AR, Kasten M, Priestley B, Chou KL, Fernandez HH, Cambi F, Langston JW, et al. Solvent exposures and Parkinson disease risk in twins. Annals of Neurology. 71: 776-84. PMID 22083847 DOI: 10.1002/Ana.22629 |
0.385 |
|
2012 |
Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism & Related Disorders. 18: 178-84. PMID 22000279 DOI: 10.1016/J.Parkreldis.2011.09.023 |
0.425 |
|
2012 |
Fernandez HH. Parkinson disease: In reply Cleveland Clinic Journal of Medicine. 79. DOI: 10.3949/ccjm.79c:04007 |
0.305 |
|
2012 |
Salardini A, Rodriguez R, Malaty I, Okun M, Fernandez H. Depressive Symptoms in Parkinson Disease as Measured by Beck's Depression Scale and Its Relationship to Visual Analogue Mood Scale, Motor Symptoms and the Quality of Life Measures (P06.057) Neurology. 78: P06.057-P06.057. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P06.057 |
0.418 |
|
2012 |
Odin P, Chatamra K, Espay A, Standaert D, Fernandez H, Benesh J, Robieson W, Hass S, Lenz R. 2.254 INTERIM RESULTS FROM ONGOING, LONG-TERM, OPEN-LABEL STUDY OF LEVODOPA/CARBIDOPA INTESTINAL GEL IN PATIENTS WITH PARKINSON'S DISEASE AND SEVERE MOTOR FLUCTUATIONS Parkinsonism & Related Disorders. 18: S128. DOI: 10.1016/S1353-8020(11)70578-8 |
0.409 |
|
2011 |
Hwynn N, Ul Haq I, Malaty IA, Resnick AS, Dai Y, Foote KD, Fernandez HH, Wu SS, Oyama G, Jacobson CE, Kim SK, Okun MS. Effect of Deep Brain Stimulation on Parkinson's Nonmotor Symptoms following Unilateral DBS: A Pilot Study. Parkinson's Disease. 2011: 507416. PMID 22220288 DOI: 10.4061/2011/507416 |
0.43 |
|
2011 |
Abboud H, Ahmed A, Fernandez HH. Essential tremor: choosing the right management plan for your patient. Cleveland Clinic Journal of Medicine. 78: 821-8. PMID 22135272 DOI: 10.3949/Ccjm.78A.10178 |
0.361 |
|
2011 |
Classen S, Witter DP, Lanford DN, Okun MS, Rodriguez RL, Romrell J, Malaty I, Fernandez HH. Usefulness of screening tools for predicting driving performance in people with Parkinson's disease. The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association. 65: 579-88. PMID 22026326 DOI: 10.5014/Ajot.2011.001073 |
0.441 |
|
2011 |
Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, Poewe W, Mollenhauer B, Sherer T, Frasier M, Meunier C, ... ... Fernandez H, et al. The Parkinson Progression Marker Initiative (PPMI) Progress in Neurobiology. 95: 629-635. PMID 21930184 DOI: 10.1016/J.Pneurobio.2011.09.005 |
0.427 |
|
2011 |
Oyama G, Foote KD, Iyer SS, Zeilman P, Hwynn N, Jacobson CE, Malaty IA, Fernandez HH, Rodriguez RL, Okun MS. Unilateral GPi-DBS as a treatment for levodopa-induced respiratory dyskinesia in Parkinson disease. The Neurologist. 17: 282-5. PMID 21881473 DOI: 10.1097/Nrl.0B013E318217367B |
0.41 |
|
2011 |
Morishita T, Rahman M, Foote KD, Fargen KM, Jacobson CE, Fernandez HH, Rodriguez RL, Malaty IA, Bowers D, Hass CJ, Katayama Y, Yamamoto T, Okun MS. DBS candidates that fall short on a levodopa challenge test: alternative and important indications. The Neurologist. 17: 263-8. PMID 21881468 DOI: 10.1097/Nrl.0B013E31822D1069 |
0.46 |
|
2011 |
Shemisa K, Hass CJ, Foote KD, Okun MS, Wu SS, Jacobson CE, Dai Y, Oyama G, Fernandez HH. Unilateral deep brain stimulation surgery in Parkinson's disease improves ipsilateral symptoms regardless of laterality. Parkinsonism & Related Disorders. 17: 745-8. PMID 21856205 DOI: 10.1016/J.Parkreldis.2011.07.010 |
0.38 |
|
2011 |
Hwynn N, Haq IU, Malaty IA, Resnick AS, Okun MS, Carew DS, Oyama G, Dai Y, Wu SS, Rodriguez RL, Jacobson CE, Fernandez HH. The Frequency of Nonmotor Symptoms among Advanced Parkinson Patients May Depend on Instrument Used for Assessment. Parkinson's Disease. 2011: 290195. PMID 21808724 DOI: 10.4061/2011/290195 |
0.403 |
|
2011 |
Voon V, Gao J, Brezing C, Symmonds M, Ekanayake V, Fernandez H, Dolan RJ, Hallett M. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain : a Journal of Neurology. 134: 1438-46. PMID 21596771 DOI: 10.1093/Brain/Awr080 |
0.372 |
|
2011 |
Hicks CW, Pandya MM, Itin I, Fernandez HH. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease Parkinsonism and Related Disorders. 17: 379-381. PMID 21459656 DOI: 10.1016/J.Parkreldis.2011.03.003 |
0.49 |
|
2011 |
Hwynn N, Hass CJ, Zeilman P, Romrell J, Dai Y, Wu SS, Foote KD, Subramony SH, Oyama G, Velez-Lago F, Fernandez HH, Resnick AS, Malaty IA, Okun MS. Steady or not following thalamic deep brain stimulation for essential tremor. Journal of Neurology. 258: 1643-8. PMID 21442464 DOI: 10.1007/S00415-011-5986-0 |
0.343 |
|
2011 |
Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease Current Medical Research and Opinion. 27: 907-919. PMID 21351823 DOI: 10.1185/03007995.2011.560146 |
0.478 |
|
2011 |
Zahodne LB, Susatia F, Bowers D, Ong TL, Jacobson CE, Okun MS, Rodriguez RL, Malaty IA, Foote KD, Fernandez HH. Binge eating in Parkinson's disease: prevalence, correlates and the contribution of deep brain stimulation. The Journal of Neuropsychiatry and Clinical Neurosciences. 23: 56-62. PMID 21304139 DOI: 10.1176/Appi.Neuropsych.23.1.56 |
0.401 |
|
2011 |
Gil RA, Hwynn N, Fabian T, Joseph S, Fernandez HH. Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients. Parkinsonism & Related Disorders. 17: 285-7. PMID 21296606 DOI: 10.1016/J.Parkreldis.2011.01.007 |
0.485 |
|
2011 |
Locke MC, Wu SS, Foote KD, Sassi M, Jacobson CE, Rodriguez RL, Fernandez HH, Okun MS. Weight changes in subthalamic nucleus vs globus pallidus internus deep brain stimulation: results from the COMPARE Parkinson disease deep brain stimulation cohort. Neurosurgery. 68: 1233-7; discussion 1. PMID 21273927 DOI: 10.1227/Neu.0B013E31820B52C5 |
0.345 |
|
2011 |
Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, et al. Rotenone, paraquat, and Parkinson's disease. Environmental Health Perspectives. 119: 866-72. PMID 21269927 DOI: 10.1289/Ehp.1002839 |
0.434 |
|
2011 |
Aguilar JA, Vesagas TS, Jamora RD, Teleg RA, Ledesma L, Rosales RL, Fernandez HH, Lee LV. The promise of deep brain stimulation in X-linked dystonia parkinsonism. The International Journal of Neuroscience. 121: 57-63. PMID 21244299 DOI: 10.3109/00207454.2010.541573 |
0.395 |
|
2011 |
Go CL, Rosales RL, Joya-Tanglao M, Fernandez HH. Untreated depressive symptoms among cognitively-intact, community dwelling Filipino patients with Parkinson disease. The International Journal of Neuroscience. 121: 137-41. PMID 21126107 DOI: 10.3109/00207454.2010.537414 |
0.377 |
|
2011 |
Hwynn N, Fernandez HH. Impulsive and compulsive behaviors in Parkinson disease Uncommon Causes of Movement Disorders. 84-93. DOI: 10.1017/CBO9780511977749.009 |
0.316 |
|
2010 |
Troche MS, Okun MS, Rosenbek JC, Musson N, Fernandez HH, Rodriguez R, Romrell J, Pitts T, Wheeler-Hegland KM, Sapienza CM. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. Neurology. 75: 1912-9. PMID 21098406 DOI: 10.1212/Wnl.0B013E3181Fef115 |
0.404 |
|
2010 |
Taba HA, Wu SS, Foote KD, Hass CJ, Fernandez HH, Malaty IA, Rodriguez RL, Dai Y, Zeilman PR, Jacobson CE, Okun MS. A closer look at unilateral versus bilateral deep brain stimulation: results of the National Institutes of Health COMPARE cohort. Journal of Neurosurgery. 113: 1224-9. PMID 20849215 DOI: 10.3171/2010.8.Jns10312 |
0.399 |
|
2010 |
Zahodne LB, Fernandez HH. Parkinson's psychosis. Current Treatment Options in Neurology. 12: 200-11. PMID 20842582 DOI: 10.1007/S11940-010-0072-Y |
0.472 |
|
2010 |
Nocera JR, Price C, Fernandez HH, Amano S, Vallabhajosula S, Okun MS, Hwynn N, Hass CJ. Tests of dorsolateral frontal function correlate with objective tests of postural stability in early to moderate stage Parkinson's disease. Parkinsonism & Related Disorders. 16: 590-4. PMID 20829093 DOI: 10.1016/J.Parkreldis.2010.08.008 |
0.364 |
|
2010 |
Oyama G, Fernandez HH, Foote KD, Zeilman P, Hwynn N, Jacobson CE, Malaty IA, Rodriguez RL, Okun MS. Differential response of dystonia and parkinsonism following globus pallidus internus deep brain stimulation in X-linked dystonia-parkinsonism (Lubag). Stereotactic and Functional Neurosurgery. 88: 329-33. PMID 20714213 DOI: 10.1159/000319961 |
0.392 |
|
2010 |
Troche MS, Fernandez HH. Parkinson disease: sialorrhea and Parkinson disease--novel treatment approaches. Nature Reviews. Neurology. 6: 423-4. PMID 20689564 DOI: 10.1038/Nrneurol.2010.107 |
0.464 |
|
2010 |
Jones HN, Kendall DL, Okun MS, Wu SS, Velozo C, Fernandez HH, Spencer KA, Rosenbek JC. Speech motor program maintenance, but not switching, is enhanced by left-hemispheric deep brain stimulation in Parkinson's disease. International Journal of Speech-Language Pathology. 12: 385-98. PMID 20586527 DOI: 10.3109/17549507.2010.491870 |
0.351 |
|
2010 |
Fernandez HH, Merello M. Pramipexole for depression and motor symptoms in Parkinson's disease: can we kill two birds with one stone? The Lancet. Neurology. 9: 556-7. PMID 20452824 DOI: 10.1016/S1474-4422(10)70114-9 |
0.368 |
|
2010 |
Nguyen FN, Chang YL, Okun MS, Rodriguez RL, Shapiro MA, Jacobson CE, Swartz CL, Fernandez HH. Prevalence and characteristics of punding and repetitive behaviors among Parkinson patients in North-Central Florida. International Journal of Geriatric Psychiatry. 25: 540-1. PMID 20391589 DOI: 10.1002/Gps.2324 |
0.353 |
|
2010 |
Wood MF, Nguyen FN, Okun MS, Rodriguez RL, Foote KD, Fernandez HH. The effect of deep brain stimulation surgery on repetitive behavior in Parkinson patients: A case series. Neurocase. 16: 31-6. PMID 20391184 DOI: 10.1080/13554790903193190 |
0.388 |
|
2010 |
Sedig L, Leibner J, Ramjit AL, Wu SS, Dai Y, Okun MS, Rodriguez RL, Malaty IA, Fernandez HH. Is rhinorrhea an under-recognized intrinsic symptom of Parkinson disease? A prospective pilot study. The International Journal of Neuroscience. 120: 258-60. PMID 20374072 DOI: 10.3109/00207451003615755 |
0.458 |
|
2010 |
Haq IU, Malaty IA, Okun MS, Jacobson CE, Fernandez HH, Rodriguez RR. Clonazepam and botulinum toxin for the treatment of alien limb phenomenon. The Neurologist. 16: 106-8. PMID 20220444 DOI: 10.1097/Nrl.0B013E3181A0D670 |
0.302 |
|
2010 |
Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Archives of Neurology. 67: 347-52. PMID 20212233 DOI: 10.1001/Archneurol.2010.1 |
0.409 |
|
2010 |
Mikos A, Pavon J, Bowers D, Foote KD, Resnick AS, Fernandez HH, Thomas P, Garvan C, Roy A, Okun MS. Factors related to extended hospital stays following deep brain stimulation for Parkinson's disease. Parkinsonism & Related Disorders. 16: 324-8. PMID 20202888 DOI: 10.1016/J.Parkreldis.2010.02.002 |
0.382 |
|
2010 |
Ramjit AL, Sedig L, Leibner J, Wu SS, Dai Y, Okun MS, Rodriguez RL, Malaty IA, Fernandez HH. The relationship between anosmia, constipation, and orthostasis and Parkinson's disease duration: results of a pilot study. The International Journal of Neuroscience. 120: 67-70. PMID 20128674 DOI: 10.3109/00207450903337721 |
0.469 |
|
2010 |
Graff-Radford J, Foote KD, Mikos AE, Bowers D, Fernandez HH, Rosado CA, Rodriguez RL, Malaty IA, Haq IU, Jacobson CE, Okun MS. Mood and motor effects of thalamic deep brain stimulation surgery for essential tremor. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 17: 1040-6. PMID 20113336 DOI: 10.1111/J.1468-1331.2010.02958.X |
0.335 |
|
2010 |
Leibner J, Ramjit A, Sedig L, Dai Y, Wu SS, Jacobson C, Okun MS, Rodriguez RL, Malaty IA, Fernandez HH. The impact of and the factors associated with drooling in Parkinson's disease. Parkinsonism & Related Disorders. 16: 475-7. PMID 20064737 DOI: 10.1016/J.Parkreldis.2009.12.003 |
0.449 |
|
2010 |
Voon V, Reynolds B, Brezing C, Gallea C, Skaljic M, Ekanayake V, Fernandez H, Potenza MN, Dolan RJ, Hallett M. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology. 207: 645-59. PMID 19838863 DOI: 10.1007/S00213-009-1697-Y |
0.413 |
|
2010 |
Fernandez HH, Greeley DR, Zweig RM, Wojcieszek J, Mori A, Sussman NM. Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial Parkinsonism and Related Disorders. 16: 16-20. PMID 19616987 DOI: 10.1016/J.Parkreldis.2009.06.008 |
0.473 |
|
2010 |
Bernal-Pacheco O, Fernandez HH. Psychosis Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and Management. 153-162. DOI: 10.1017/CBO9781139856669.015 |
0.357 |
|
2010 |
Nocera J, Vallabhajosula S, Zahodne L, Sozda C, Bowers D, Fernandez H, Hass C. 097 IS APATHY ASSOCIATED WITH POSTURAL CONTROL IN PARKINSON'S DISEASE? Parkinsonism & Related Disorders. 16: S28-S29. DOI: 10.1016/S1353-8020(10)70098-5 |
0.398 |
|
2010 |
Nocera J, Amano S, Vallabhajosula S, Fernandez H, Hass C. 096 GAIT PERFORMANCE AND COGNITIVE FUNCTION IN PARKINSON'S DISEASE Parkinsonism & Related Disorders. 16: S28. DOI: 10.1016/S1353-8020(10)70097-3 |
0.365 |
|
2009 |
Cooper CA, Jadidian A, Paggi M, Romrell J, Okun MS, Rodriguez RL, Fernandez HH. Prevalence of hypersexual behavior in Parkinson's disease patients: Not restricted to males and dopamine agonist use. International Journal of General Medicine. 2: 57-61. PMID 20360887 DOI: 10.2147/Ijgm.S4674 |
0.454 |
|
2009 |
Fernandez HH, Okun MS, Rodriguez RL, Malaty IA, Romrell J, Sun A, Wu SS, Pillarisetty S, Nyathappa A, Eisenschenk S. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. The International Journal of Neuroscience. 119: 2196-205. PMID 19916848 DOI: 10.3109/00207450903222758 |
0.399 |
|
2009 |
Classen S, McCarthy DP, Shechtman O, Awadzi KD, Lanford DN, Okun MS, Rodriguez RL, Romrell J, Bridges S, Kluger B, Fernandez HH. Useful field of view as a reliable screening measure of driving performance in people with Parkinson's disease: results of a pilot study. Traffic Injury Prevention. 10: 593-8. PMID 19916131 DOI: 10.1080/15389580903179901 |
0.434 |
|
2009 |
Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Federoff M, Klein C, Goate A, Perlmutter J, ... ... Fernandez HH, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics. 41: 1308-12. PMID 19915575 DOI: 10.1038/Ng.487 |
0.393 |
|
2009 |
Malaty IA, Fernandez HH. Role of rasagiline in treating Parkinson's disease: Effect on disease progression. Therapeutics and Clinical Risk Management. 5: 413-9. PMID 19753135 DOI: 10.2147/Tcrm.S4321 |
0.485 |
|
2009 |
Stewart KC, Fernandez HH, Okun MS, Alberts JL, Malaty IA, Rodriguez RL, Hass CJ. Effects of dopaminergic medication on objective tasks of deftness, bradykinesia and force control. Journal of Neurology. 256: 2030-5. PMID 19597692 DOI: 10.1007/S00415-009-5235-Y |
0.398 |
|
2009 |
Stewart KC, Fernandez HH, Okun MS, Rodriguez RL, Jacobson CE, Hass CJ. Side onset influences motor impairments in Parkinson disease. Parkinsonism & Related Disorders. 15: 781-3. PMID 19447063 DOI: 10.1016/J.Parkreldis.2009.02.001 |
0.326 |
|
2009 |
Fernandez HH, See RH, Gary MF, Bowers D, Rodriguez RL, Jacobson C, Okun MS. Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performance. Journal of Geriatric Psychiatry and Neurology. 22: 223-7. PMID 19429848 DOI: 10.1177/0891988709335792 |
0.395 |
|
2009 |
Susatia F, Fernandez HH. Drug-induced parkinsonism. Current Treatment Options in Neurology. 11: 162-9. PMID 19364450 DOI: 10.1007/S11940-009-0019-3 |
0.389 |
|
2009 |
Zahodne LB, Okun MS, Foote KD, Fernandez HH, Rodriguez RL, Wu SS, Kirsch-Darrow L, Jacobson CE, Rosado C, Bowers D. Greater improvement in quality of life following unilateral deep brain stimulation surgery in the globus pallidus as compared to the subthalamic nucleus. Journal of Neurology. 256: 1321-9. PMID 19363633 DOI: 10.1007/S00415-009-5121-7 |
0.414 |
|
2009 |
Plowman-Prine EK, Okun MS, Sapienza CM, Shrivastav R, Fernandez HH, Foote KD, Ellis C, Rodriguez AD, Burkhead LM, Rosenbek JC. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. Neurorehabilitation. 24: 131-44. PMID 19339752 DOI: 10.3233/Nre-2009-0462 |
0.312 |
|
2009 |
Okun MS, Fernandez HH, Wu SS, Kirsch-Darrow L, Bowers D, Bova F, Suelter M, Jacobson CE, Wang X, Gordon CW, Zeilman P, Romrell J, Martin P, Ward H, Rodriguez RL, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Annals of Neurology. 65: 586-95. PMID 19288469 DOI: 10.1002/Ana.21596 |
0.356 |
|
2009 |
Kirsch-Darrow L, Zahodne LB, Hass C, Mikos A, Okun MS, Fernandez HH, Bowers D. How cautious should we be when assessing apathy with the Unified Parkinson's Disease Rating Scale? Movement Disorders : Official Journal of the Movement Disorder Society. 24: 684-8. PMID 19185011 DOI: 10.1002/Mds.22437 |
0.342 |
|
2009 |
Mikos AE, Springer US, Nisenzon AN, Kellison IL, Fernandez HH, Okun MS, Bowers D. Awareness of expressivity deficits in non-demented Parkinson disease. The Clinical Neuropsychologist. 23: 805-17. PMID 19169938 DOI: 10.1080/13854040802572434 |
0.374 |
|
2009 |
Zahodne LB, Young S, Kirsch-Darrow L, Nisenzon A, Fernandez HH, Okun MS, Bowers D. Examination of the Lille Apathy Rating Scale in Parkinson disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 677-83. PMID 19133658 DOI: 10.1002/Mds.22441 |
0.436 |
|
2009 |
Okun MS, Fernandez HH. Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients? Neurology. 72: 868-9. PMID 19092111 DOI: 10.1212/01.Wnl.0000338145.24512.02 |
0.421 |
|
2009 |
Zahodne LB, Okun MS, Foote KD, Fernandez HH, Rodriguez RL, Kirsch-Darrow L, Bowers D. Cognitive declines one year after unilateral deep brain stimulation surgery in Parkinson's disease: a controlled study using reliable change. The Clinical Neuropsychologist. 23: 385-405. PMID 18821180 DOI: 10.1080/13854040802360582 |
0.439 |
|
2009 |
Cooper CA, Mikos AE, Wood MF, Kirsch-Darrow L, Jacobson CE, Okun MS, Rodriguez RL, Bowers D, Fernandez HH. Does laterality of motor impairment tell us something about cognition in Parkinson disease? Parkinsonism & Related Disorders. 15: 315-7. PMID 18793864 DOI: 10.1016/J.Parkreldis.2008.07.009 |
0.322 |
|
2009 |
Siddiqui MS, Fernandez HH, Garvan CW, Kirsch-Darrow L, Bowers D, Rodriguez RL, Jacobson CE, Rosado C, Vaidyanathan S, Foote KD, Okun MS. Inappropriate crying and laughing in Parkinson disease and movement disorders. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 10: 234-40. PMID 18609421 DOI: 10.1080/15622970701639445 |
0.455 |
|
2009 |
Howe LL, Kellison IL, Fernandez HH, Okun MS, Bowers D. Neuropsychological profile of a Filipino gentleman with X-linked dystonia-parkinsonism: a case report of Lubag disease. The Clinical Neuropsychologist. 23: 100-17. PMID 18609312 DOI: 10.1080/13854040801894714 |
0.417 |
|
2009 |
Cooper CA, Jadidian A, Paggi M, Romrell J, Okun MS, Rodriguez RL, Fernandez HH. Prevalence of hypersexual behavior in Parkinson's disease patients: Not restricted to males and dopamine agonist use International Journal of General Medicine. 2: 57-61. |
0.349 |
|
2008 |
Won MS, Mikos A, Hurd M, Fernandez H, Eskin T, Romrell J, Okun MS. Tardive parkinsonism in a bipolar patient: post-mortem examination supports a physiological rather than pathological dysfunction. Neurocase. 15: 66-9. PMID 19235627 DOI: 10.1080/13554790802613033 |
0.465 |
|
2008 |
Ellis TM, Foote KD, Fernandez HH, Sudhyadhom A, Rodriguez RL, Zeilman P, Jacobson CE, Okun MS. Reoperation for suboptimal outcomes after deep brain stimulation surgery. Neurosurgery. 63: 754-60; discussion 7. PMID 18981887 DOI: 10.1227/01.Neu.0000325492.58799.35 |
0.392 |
|
2008 |
Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs & Aging. 25: 665-82. PMID 18665659 DOI: 10.2165/00002512-200825080-00004 |
0.482 |
|
2008 |
Stewart KC, Fernandez HH, Okun MS, Jacobson CE, Hass CJ. Distribution of motor impairment influences quality of life in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 1466-8. PMID 18546324 DOI: 10.1002/Mds.22162 |
0.43 |
|
2008 |
Hooper AK, Okun MS, Foote KD, Fernandez HH, Jacobson C, Zeilman P, Romrell J, Rodriguez RL. Clinical cases where lesion therapy was chosen over deep brain stimulation Stereotactic and Functional Neurosurgery. 86: 147-152. PMID 18334856 DOI: 10.1159/000120426 |
0.317 |
|
2008 |
Okun MS, Rodriguez RL, Foote KD, Sudhyadhom A, Bova F, Jacobson C, Bello B, Zeilman P, Fernandez HH. A case-based review of troubleshooting deep brain stimulator issues in movement and neuropsychiatric disorders Parkinsonism and Related Disorders. 14: 532-538. PMID 18325819 DOI: 10.1016/J.Parkreldis.2008.01.001 |
0.305 |
|
2008 |
Fernandez HH. What we have learned about sleep disorders and psychosis after nearly two centuries of Parkinson's disease. Summary and conclusions. Cns Spectrums. 13: 34-5. PMID 18323765 DOI: 10.1017/S1092852900017302 |
0.322 |
|
2008 |
Zahodne LB, Fernandez HH. Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective? Cns Spectrums. 13: 26-33. PMID 18323764 DOI: 10.1017/S1092852900017296 |
0.447 |
|
2008 |
Fernandez HH. Taking a closer look at sleep problems and psychosis in Parkinson's disease. Introduction. Cns Spectrums. 13: 4-5. PMID 18323760 DOI: 10.1017/S1092852900017259 |
0.317 |
|
2008 |
Okun MS, Fernandez HH, Foote KD, Murphy TK, Goodman WK. Avoiding deep brain stimulation failures in Tourette syndrome Journal of Neurology, Neurosurgery and Psychiatry. 79: 111-112. PMID 18202200 DOI: 10.1136/Jnnp.2007.135715 |
0.327 |
|
2008 |
Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 484-500. PMID 18175343 DOI: 10.1002/Mds.21875 |
0.414 |
|
2008 |
Fernandez HH, McCown KM, Romrell J, Trieschmann ME, Friedman JH, Jacobson CE, Okun MS. New-Onset Diabetes Mellitus among Parkinsonian Patients Treated with Long-term Quetiapine Drug Target Insights. 3: DTI.S650. DOI: 10.4137/Dti.S650 |
0.311 |
|
2008 |
Chen JJ, Trombetta DP, Fernandez HH. Palliative management of Parkinson disease: Focus on nonmotor, distressing symptoms Journal of Pharmacy Practice. 21: 262-272. DOI: 10.1177/0897190008318370 |
0.417 |
|
2007 |
Riggeal BD, Crucian GP, Seignourel P, Jacobson CE, Okun MS, Rodriguez Rl, Fernandez HH. Cognitive decline tracks motor progression and not disease duration in Parkinson patients. Neuropsychiatric Disease and Treatment. 3: 955-8. PMID 19300633 DOI: 10.2147/Ndt.S2237 |
0.442 |
|
2007 |
Shapiro MA, Chang YL, Munson SK, Jacobson CE, Rodriguez RL, Skidmore FM, Okun MS, Fernandez HH. The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists. Neuropsychiatric Disease and Treatment. 3: 161-7. PMID 19300546 DOI: 10.2147/Nedt.2007.3.1.161 |
0.44 |
|
2007 |
Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease Pharmacotherapy. 27. PMID 18041937 DOI: 10.1592/Phco.27.12Part2.174S |
0.355 |
|
2007 |
Haq IU, Lewitt PA, Fernandez HH. Apomorphine therapy in Parkinson's disease: a review. Expert Opinion On Pharmacotherapy. 8: 2799-809. PMID 17956200 DOI: 10.1517/14656566.8.16.2799 |
0.431 |
|
2007 |
Rodriguez RL, Fernandez HH, Haq I, Okun MS. Pearls in patient selection for deep brain stimulation. The Neurologist. 13: 253-60. PMID 17848865 DOI: 10.1097/Nrl.0B013E318095A4D5 |
0.315 |
|
2007 |
Chen JJ, Fernandez HH. Community and long-term care management of Parkinson's disease in the elderly: Focus on monoamine oxidase type B inhibitors Drugs and Aging. 24: 663-680. PMID 17702535 DOI: 10.2165/00002512-200724080-00004 |
0.403 |
|
2007 |
Johnson J, Paisán-RuÃz C, Lopez G, Crews C, Britton A, Malkani R, Evans EW, McInerney-Leo A, Jain S, Nussbaum RL, Foote KD, Mandel RJ, Crawley A, Reimsnider S, Fernandez HH, et al. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. Neuro-Degenerative Diseases. 4: 386-91. PMID 17622782 DOI: 10.1159/000105160 |
0.398 |
|
2007 |
Kenney C, Fernandez HH, Okun MS. Role of deep brain stimulation targeted to the pedunculopontine nucleus in Parkinson's disease Expert Review of Neurotherapeutics. 7: 585-589. PMID 17563240 DOI: 10.1586/14737175.7.6.585 |
0.474 |
|
2007 |
Fernandez HH, Chen JJ. Monamine oxidase inhibitors: Current and emerging agents for Parkinson disease Clinical Neuropharmacology. 30: 150-168. PMID 17545750 DOI: 10.1097/01.Wnf.0000240956.49315.Be |
0.478 |
|
2007 |
Halkias IA, Haq I, Huang Z, Fernandez HH. When should levodopa therapy be initiated in patients with Parkinson's disease? Drugs & Aging. 24: 261-73. PMID 17432922 DOI: 10.2165/00002512-200724040-00001 |
0.482 |
|
2007 |
Okun MS, Rodriguez RL, Mikos A, Miller K, Kellison I, Kirsch-Darrow L, Wint DP, Springer U, Fernandez HH, Foote KD, Crucian G, Bowers D. Deep brain stimulation and the role of the neuropsychologist. The Clinical Neuropsychologist. 21: 162-89. PMID 17366283 DOI: 10.1080/13825580601025940 |
0.355 |
|
2007 |
Nguyen FN, Pauly RR, Okun MS, Fernandez HH. Punding as a complication of brain stem stroke? Report of a case Stroke. 38: 1390-1392. PMID 17332454 DOI: 10.1161/01.Str.0000260088.07611.6E |
0.37 |
|
2007 |
Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1061-8. PMID 17266092 DOI: 10.1002/Mds.21382 |
0.43 |
|
2007 |
Xiromerisiou G, Hadjigeorgiou GM, Eerola J, Fernandez HH, Tsimourtou V, Mandel R, Hellström O, Gwinn-Hardy K, Okun MS, Tienari PJ, Singleton AB. BDNF tagging polymorphisms and haplotype analysis in sporadic Parkinson's disease in diverse ethnic groups. Neuroscience Letters. 415: 59-63. PMID 17229524 DOI: 10.1016/J.Neulet.2006.12.038 |
0.385 |
|
2007 |
Quencer K, Okun MS, Crucian G, Fernandez HH, Skidmore F, Heilman KM. Limb-kinetic apraxia in Parkinson disease. Neurology. 68: 150-1. PMID 17151340 DOI: 10.1212/01.Wnl.0000250331.35912.A5 |
0.434 |
|
2007 |
Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, Shults CW, Wojcieszek J, Foroud T, Shults C, Marshall F, Oakes D, Shinaman A, Marder K, Conneally PM, ... ... Fernandez H, et al. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation Movement Disorders. 22: 254-257. PMID 17149721 DOI: 10.1002/Mds.21233 |
0.409 |
|
2007 |
Williams LN, Seignourel P, Crucian GP, Okun MS, Rodriguez RL, Skidmore FM, Foster PS, Jacobson CE, Romrell J, Bowers D, Fernandez HH. Laterality, region, and type of motor dysfunction correlate with cognitive impairment in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 141-5. PMID 17089386 DOI: 10.1002/Mds.21220 |
0.318 |
|
2006 |
Scholz S, Mandel RJ, Fernandez HH, Foote KD, Rodriguez RL, Barton E, Munson S, Singleton A, Okun MS. LRRK2 mutations in a clinic-based cohort of Parkinson's disease. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 13: 1298-301. PMID 17116211 DOI: 10.1111/J.1468-1331.2006.01472.X |
0.402 |
|
2006 |
Bowers D, Miller K, Mikos A, Kirsch-Darrow L, Springer U, Fernandez H, Foote K, Okun M. Startling facts about emotion in Parkinson's disease: blunted reactivity to aversive stimuli. Brain : a Journal of Neurology. 129: 3356-65. PMID 17095520 DOI: 10.1093/Brain/Awl301 |
0.415 |
|
2006 |
Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC, Shults C, Marshall F, Oakes D, Shinaman A, Marder K, Conneally PM, ... ... Fernandez H, et al. Mutations in LRRK2 other than G2019S are rare in a north-American based sample of familial Parkinson's didease Movement Disorders. 21: 2257-2260. PMID 17078063 DOI: 10.1002/Mds.21162 |
0.339 |
|
2006 |
Fung HC, Scholz S, Matarin M, Simón-Sánchez J, Hernandez D, Britton A, Gibbs JR, Langefeld C, Stiegert ML, Schymick J, Okun MS, Mandel RJ, Fernandez HH, Foote KD, RodrÃguez RL, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. The Lancet. Neurology. 5: 911-6. PMID 17052657 DOI: 10.1016/S1474-4422(06)70578-6 |
0.356 |
|
2006 |
Kirsch-Darrow L, Fernandez HH, Fernandez HF, Marsiske M, Okun MS, Bowers D. Dissociating apathy and depression in Parkinson disease. Neurology. 67: 33-8. PMID 16832074 DOI: 10.1212/01.Wnl.0000230572.07791.22 |
0.301 |
|
2006 |
Skidmore FM, Rodriguez RL, Fernandez HH, Goodman WK, Foote KD, Okun MS. Lessons learned in deep brain stimulation for movement and neuropsychiatric disorders Cns Spectrums. 11: 521-537. PMID 16816792 DOI: 10.1017/S1092852900013559 |
0.386 |
|
2006 |
Shapiro MA, Chang YL, Munson SK, Okun MS, Fernandez HH. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Parkinsonism & Related Disorders. 12: 392-5. PMID 16730214 DOI: 10.1016/J.Parkreldis.2006.01.010 |
0.416 |
|
2006 |
Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, Louis ED, Mulligan T, Foster PS, Shenal BV, Armaghani SJ, Jacobson C, Wu S, Crucian G. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study. Archives of Neurology. 63: 729-35. PMID 16682542 DOI: 10.1001/Archneur.63.5.729 |
0.439 |
|
2006 |
Foote KD, Seignourel P, Fernandez HH, Romrell J, Whidden E, Jacobson C, Rodriguez RL, Okun MS. Dual electrode thalamic deep brain stimulation for the treatment of posttraumatic and multiple sclerosis tremor Neurosurgery. 58. PMID 16582651 DOI: 10.1227/01.Neu.0000192692.95455.Fd |
0.332 |
|
2006 |
Chou KL, Fernandez HH. Combating psychosis in Parkinson's disease patients: The use of antipsychotic drugs Expert Opinion On Investigational Drugs. 15: 339-349. PMID 16548784 DOI: 10.1517/13543784.15.4.339 |
0.458 |
|
2006 |
Scholz SW, Xiromerisiou G, Fung HC, Eerola J, Hellström O, Papadimitriou A, Hadjigeorgiou GM, Tienari PJ, Fernandez HH, Mandel R, Okun MS, Gwinn-Hardy K, Singleton AB. The human prion gene M129V polymorphism is not associated with idiopathic Parkinson's disease in three distinct populations. Neuroscience Letters. 395: 227-9. PMID 16298483 DOI: 10.1016/J.Neulet.2005.10.081 |
0.324 |
|
2005 |
Fernandez HH, Crucian GP, Okun MS, Price CC, Bowers D. Mild cognitive impairment in Parkinson's disease: the challenge and the promise. Neuropsychiatric Disease and Treatment. 1: 37-50. PMID 18568128 DOI: 10.2147/Nedt.1.1.37.52295 |
0.438 |
|
2005 |
Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. Journal of Neurology, Neurosurgery, and Psychiatry. 76: 934-9. PMID 15965198 DOI: 10.1136/Jnnp.2004.050682 |
0.452 |
|
2005 |
Friedman JH, Trieschmann ME, Myers RH, Fernandez HH. Monozygotic twins discordant for Huntington disease after 7 years. Archives of Neurology. 62: 995-7. PMID 15956172 DOI: 10.1001/Archneur.62.6.995 |
0.32 |
|
2005 |
Okun MS, Tagliati M, Pourfar M, Fernandez HH, Rodriguez RL, Alterman RL, Foote KD. Management of referred deep brain stimulation failures: A retrospective analysis from 2 Movement Disorders Centers Archives of Neurology. 62: 1250-1255. PMID 15956104 DOI: 10.1001/Archneur.62.8.Noc40425 |
0.302 |
|
2005 |
Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease Movement Disorders. 20: 104-115. PMID 15390047 DOI: 10.1002/Mds.20260 |
0.442 |
|
2005 |
Fernandez HH, Okun MS. Reply: Rebound psychosis in Parkinson's disease Movement Disorders. 20: 515-515. DOI: 10.1002/Mds.20431 |
0.397 |
|
2004 |
Rogaeva E, Johnson J, Lang AE, Gulick C, Gwinn-Hardy K, Kawarai T, Sato C, Morgan A, Werner J, Nussbaum R, Petit A, Okun MS, McInerney A, Mandel R, Groen JL, ... Fernandez HH, et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Archives of Neurology. 61: 1898-904. PMID 15596610 DOI: 10.1001/Archneur.61.12.1898 |
0.378 |
|
2004 |
Fernandez HH, Friedman JH, Lansang MC, Factor SA, Molho ES, Coskun DJ. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism & Related Disorders. 10: 439-41. PMID 15465403 DOI: 10.1016/J.Parkreldis.2004.04.007 |
0.382 |
|
2004 |
Ready RE, Friedman J, Grace J, Fernandez H. Testosterone deficiency and apathy in Parkinson's disease: A pilot study Journal of Neurology, Neurosurgery and Psychiatry. 75: 1323-1326. PMID 15314124 DOI: 10.1136/Jnnp.2003.032284 |
0.426 |
|
2004 |
Wint DP, Okun MS, Fernandez HH. Psychosis in Parkinson's disease Journal of Geriatric Psychiatry and Neurology. 17: 127-136. PMID 15312276 DOI: 10.1177/0891988704267457 |
0.467 |
|
2004 |
Al-Yacoub M, Friedman JH, Fernandez HH. Hemiballismus from a parietal stroke in a Parkinson patient Movement Disorders. 19: 986-988. PMID 15300673 DOI: 10.1002/Mds.20204 |
0.438 |
|
2004 |
Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients Movement Disorders. 19: 831-833. PMID 15254945 DOI: 10.1002/Mds.20051 |
0.336 |
|
2004 |
Okun MS, Fernandez HH, Pedraza O, Misra M, Lyons KE, Pahwa R, Tarsy D, Scollins L, Corapi K, Friehs GM, Grace J, Romrell J, Foote KD. Development and initial validation of a screening tool for Parkinson disease surgical candidates. Neurology. 63: 161-3. PMID 15249630 DOI: 10.1212/01.Wnl.0000133122.14824.25 |
0.458 |
|
2004 |
Fernandez HH, Lannon MC, Trieschmann ME, Friedman JH. Botulinum toxin type B for gait freezing in Parkinson's disease Medical Science Monitor. 10. PMID 15232500 |
0.341 |
|
2004 |
Fernandez HH, Trieschmann ME, Friedman JH. Aripraxole for Drug-induced Psychosis in Parkinson Disease: Preliminary Experience Clinical Neuropharmacology. 27: 4-5. PMID 15090928 DOI: 10.1097/00002826-200401000-00003 |
0.402 |
|
2004 |
Woods RJ, Cervone RL, Fernandez HH. Common neurologic disorders affecting the foot Journal of the American Podiatric Medical Association. 94: 104-117. PMID 15028788 DOI: 10.7547/87507315-94-2-104 |
0.336 |
|
2004 |
Friedman JH, Fernandez HH, Trieschmann MM. Parkinsonism in a Nursing Home: Underrecognition Journal of Geriatric Psychiatry and Neurology. 17: 39-41. PMID 15018697 DOI: 10.1177/0891988703262001 |
0.423 |
|
2003 |
Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of dementia with Lewy bodies Expert Opinion On Pharmacotherapy. 4: 2027-2037. PMID 14596656 DOI: 10.1517/14656566.4.11.2027 |
0.436 |
|
2003 |
Romrell J, Fernandez HH, Okun MS. Rationale for current therapies in Parkinson's disease Expert Opinion On Pharmacotherapy. 4: 1747-1761. PMID 14521485 DOI: 10.1517/14656566.4.10.1747 |
0.446 |
|
2003 |
Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: Safety considerations Drug Safety. 26: 643-659. PMID 12814332 DOI: 10.2165/00002018-200326090-00004 |
0.475 |
|
2003 |
Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes Neurologist. 9: 16-27. PMID 12801428 DOI: 10.1097/01.Nrl.0000038585.58012.97 |
0.334 |
|
2003 |
Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 510-4. PMID 12722164 DOI: 10.1002/Mds.10374 |
0.404 |
|
2003 |
Friedman JH, Skeete R, Fernandez HH. Unrecognized Parkinsonism in acute care medical patients receiving neurological consultations [3] Journals of Gerontology - Series a Biological Sciences and Medical Sciences. 58: 94-95. PMID 12560420 DOI: 10.1093/Gerona/58.1.M94-A |
0.316 |
|
2002 |
Friedman JH, Fernandez HH. Atypical antipsychotics in Parkinson-sensitive populations Journal of Geriatric Psychiatry and Neurology. 15: 156-170. PMID 12230086 DOI: 10.1177/089198870201500307 |
0.447 |
|
2002 |
Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies Journal of Clinical Psychiatry. 63: 513-515. PMID 12088163 DOI: 10.4088/Jcp.V63N0608 |
0.484 |
|
2002 |
Friedman JH, Fernandez HH, Sikirica M, Stopa E, Friehs G. Stroke induced by gamma knife pallidotomy: Autopsy result Neurology. 58: 1695-1697. PMID 12058106 DOI: 10.1212/Wnl.58.11.1695-A |
0.307 |
|
2001 |
Fernandez HH, Tabamo REJ, David RR, Friedman JH. Predictors of depressive symptoms among spouse caregivers in Parkinson's disease Movement Disorders. 16: 1123-1125. PMID 11748746 DOI: 10.1002/Mds.1196 |
0.437 |
|
2001 |
Friedman JH, Fernandez HH. Autopsy follow-up of a patient with schizophrenia and presumed idiopathic Parkinson's disease Clinical Neuropharmacology. 24: 120-121. PMID 11307051 DOI: 10.1097/00002826-200103000-00012 |
0.377 |
|
2001 |
Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-Year follow-up Neurology. 56: 805-807. PMID 11274325 DOI: 10.1212/Wnl.56.6.805 |
0.381 |
|
2001 |
FRIEDMAN J, FERNANDEZ H, FACTOR S. Treatment of Psychosis in Parkinson's Disease Journal of the American Medical Directors Association. 2: 99-99. DOI: 10.1016/S1525-8610(04)70170-X |
0.42 |
|
2001 |
Friedman JH, Fernandez HH, Factor SA, Rangu S, Rowland FN. Treatment of psychosis in parkinson's disease (multiple letters) Journal of the American Medical Directors Association. 2: 99-100. |
0.306 |
|
2000 |
Fernandez HH, Lapane KL, Ott BR, Friedman JH. Gender differences in the frequency and treatment of behavior problems in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 490-496. PMID 28470738 DOI: 10.1002/1531-8257(200005)15:3<490::Aid-Mds1011>3.0.Co;2-E |
0.41 |
|
2000 |
Fernandez HH, Lapane KL. Estrogen use among nursing home residents with a diagnosis of Parkinson's disease Movement Disorders. 15: 1119-1124. PMID 11104194 DOI: 10.1002/1531-8257(200011)15:6<1119::Aid-Mds1009>3.0.Co;2-0 |
0.365 |
|
2000 |
Fernandez HH, Friedman JH, Famiglietti EV. Probable Cornelia de Lange syndrome with progressive parkinsonism and dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 749-51. PMID 10928594 DOI: 10.1002/1531-8257(200007)15:4<749::Aid-Mds1028>3.0.Co;2-P |
0.337 |
|
2000 |
Tabamo RE, Fernandez HH, Friedman JH, Simon DK. Young-onset Parkinson's disease: a clinical pathologic description of two siblings. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 744-6. PMID 10928592 DOI: 10.1002/1531-8257(200007)15:4<744::Aid-Mds1026>3.0.Co;2-# |
0.4 |
|
2000 |
Fernandez HH, Lannon MC, Friedman JH, Abbott BP. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease Movement Disorders. 15: 579-581. PMID 10830427 DOI: 10.1002/1531-8257(200005)15:3<579::Aid-Mds1024>3.0.Co;2-0 |
0.388 |
|
2000 |
Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease Movement Disorders. 15: 173-176. PMID 10634264 DOI: 10.1002/1531-8257(200001)15:1<173::Aid-Mds1032>3.0.Co;2-T |
0.345 |
|
2000 |
Friedman JH, Fernandez HH. The nonmotor problems of Parkinson's disease Neurologist. 6: 18-27. DOI: 10.1097/00127893-200006010-00004 |
0.491 |
|
1999 |
Lapane KL, Fernandez HH, Friedman JH. Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities Pharmacotherapy. 19: 1321-1327. PMID 10555938 DOI: 10.1592/Phco.19.16.1321.30877 |
0.42 |
|
1999 |
Fernandez HH, Friedman JH. Funding on L-Dopa Movement Disorders. 14: 836-838. PMID 10495047 DOI: 10.1002/1531-8257(199909)14:5<836::Aid-Mds1018>3.0.Co;2-0 |
0.425 |
|
1999 |
Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 484-7. PMID 10348474 DOI: 10.1002/1531-8257(199905)14:3<484::Aid-Mds1016>3.0.Co;2-B |
0.498 |
|
1999 |
Fernandez HH, Friedman JH. The role of atypical antipsychotics in the treatment of movement disorders Cns Drugs. 11: 467-483. DOI: 10.2165/00023210-199911060-00005 |
0.417 |
|
1999 |
Fernandez HH, Friedman JH, Rosenfeld M, Jacques C, Cummings J. QUETIAPINE FOR THE TREATMENT OF DRUG-INDUCED PSYCHOSIS IN PARKINSON's DISEASE American Journal of Geriatric Psychiatry. 7: 32-33. DOI: 10.1097/00019442-199911001-00105 |
0.385 |
|
1998 |
Fernandez HH, Durso R. Clozapine for dopaminergic-induced paraphilias in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 597-8. PMID 9613761 DOI: 10.1002/Mds.870130338 |
0.31 |
|
Show low-probability matches. |